

ATTORNEYS AT LAW 900 THIRD AVENUE, 5™ FL NEW YORK, NEW YORK 10022 TEL: 646-627-7326 FAX: 646-224-9844 WWW.OFSINKLLC.COM

June 27, 2013

## **By OTC Disclosure and News Services**

OTC Markets Group Inc. 304 Hudson Street, 3<sup>rd</sup> Floor New York, NY 10013

Re: Redijet, Inc.

Ladies and Gentlemen:

We are counsel to Redijet, Inc., a Colorado corporation (the "Company" or the "Issuer"). We are a legal resident of the United States and licensed to practice law in New York. We note that we are members of the Bar of the State of New York and do not represent ourselves to be experts in the laws of any other jurisdiction, except for the laws of the United States of America.

We provide general legal counsel to the Company pertaining to its business affairs, including, but not limited to, the purpose of rendering this opinion letter (this "Letter"). OTC Markets Group Inc. ("OTC Markets Group") may rely upon this Letter in determining whether the Company has made adequate current information publicly available in accordance with Rule 144(c)(2) under the Securities Act of 1933 (the "Securities Act").

In rendering this Letter, we have (a) assumed (i) the genuineness of all signatures on all documents examined by us, (ii) the authenticity of all documents submitted to us as originals, and (iii) the conformity to original documents of all documents submitted to us as photostatic or conformed copies and the authenticity of the originals of such copies; and (b) relied on (i) certificates of public officials and (ii) as to matters of fact, statements and certificates of officers and representatives of the Company, including, but not limited to, the Certificate of Officer regarding filing with OTC Disclosure and News Service, dated June 21, 2013.

The opinions and conclusions contained in this Letter are based upon documentation and facts made available by the Company to us, and are solely based on the accuracy of those documents and facts. In the event that the facts and information in any or all of such documents are determined not to be true, this opinion is rescinded and to be deemed null and void.

We have further addressed such questions of law that we have deemed necessary and/or appropriate for the purpose of rendering this Letter.

This Letter is respectfully submitted on behalf of the Company to be posted by the Issuer and published, accompanying the Issuer's disclosure(s), through the OTC Disclosure and News Service in accordance with and/or pursuant to OTC Disclosure and News Service guidelines.

This Letter covers the laws of the United States and does not depend on another law firm's opinion or letter. We are permitted to practice before the U.S. Securities and Exchange Commission (the "SEC") without prohibition.

Mark Dresner is responsible for the preparation of the financial statements of the Company. The financial statements are not audited. To the best of our knowledge and without independent investigation, Mark Dresner has a bachelor degree in Business Administration and has experience in preparing financial statements for a number of private companies and public companies over the past 30 years and thus has sufficient knowledge and expertise to adequately prepare such financial statements. We have not met with Mark Dresner, nor have we reviewed the materials on which the financial statements are based.

The Company's transfer agent is Quicksilver Stock Transfer, LLC ("Quicksilver"). Quicksilver is duly registered with the SEC. We have relied upon and reviewed a shareholder list supplied by Quicksilver which we used to confirm the number of the outstanding shares as set forth in the Information (as defined below).

We have (i) met personally with the management of the Company and the majority of the directors; (ii) reviewed the information described further below, as filed by the Issuer, with the OTC Disclosure and News Service; and (iii) discussed the Information with management and the majority of the directors of the Company.

To the best of our knowledge and after inquiry of management and the directors of the Company, no 5% holder of securities of the Company, the Company or counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

The documents containing information concerning the Company that are publicly available and which we have reviewed as filed with the OTC Disclosure and News Service in preparation for rendering this Letter (the "Information") are set forth herein below along with the date each document was posted through the OTC Disclosure and News Service.

Type of Document filed	Document Description	Date Released/ Posted
Initial Disclosure Statement	Initial Disclosure Statement	June 21, 2013
Annual Report	Financial Statement December 31, 2011	June 21, 2013



Annual Report	Financial Statement December 31, 2012	June 21, 2013
Quarterly Report	Financial Statement March 31, 2013	June 21, 2013

Based upon the foregoing and subject to the qualifications hereinafter set forth, we are of the opinion that the Information reviewed, as herein described and detailed above as filed by the Company with and published by the OTC Disclosure and News Service, except that no opinion is given with respect to Rule 15c2-11(a)(5)(xiv), (xv) and (xvi) under the Securities Exchange Act of 1934 (the "Exchange Act"):

- 1. Constitutes "adequate current public information" concerning the Issuer's securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act,
- 2. Includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Issuer's securities under Rule 15c2-11 under the Exchange Act,
- 3. Complies as to form with the OTC Markets Group's Guidelines for Providing Adequate Current Information, and
- 4. Has been posted through the OTC Disclosure and News Service.

This Letter may be relied upon by OTC Markets Group, but may not be used or relied on by any other person for any other purpose whatsoever, without in each instance the undersigned's prior written consent. OTC Markets Group is granted full and complete permission and rights to publish this Letter through the OTC Disclosure and News Service for viewing by the public or regulators.

Very truly yours,

/s/ Ofsink, LLC

OFSINK, LLC

